1. Fitzal F, Riedl O, Mittlböck M, Dubsky P, Bartsch R, Steger G, et al. Oncologic safety of breast conserving surgery after tumour downsizing by neoadjuvant therapy: a retrospective single centre cohort study. Breast Cancer Res Treat 2011;127:121-8.
2. Golshan M, Cirrincione CT, Sikov WM, Berry DA, Jasinski S, Weisberg TF, et al. Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance). Ann Surg 2015;262:434-9.
4. Mo H, Kim Y, Rhu J, Lee KH, Kim TY, Im SA, et al. Actual conversion rate from total mastectomy to breast conservation after neoadjuvant chemotherapy for stages II–III breast cancer patients. J Breast Dis 2017;5:51-6.
6. Ihemelandu CU, Naab TJ, Mezghebe HM, Makambi KH, Siram SM, Leffall LD Jr, et al. Treatment and survival outcome for molecular breast cancer subtypes in black women. Ann Surg 2008;247:463-9.
7. Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat 2012;133:831-41.
8. McGuire A, Lowery AJ, Kell MR, Kerin MJ, Sweeney KJ. Locoregional recurrence following breast cancer surgery in the trastuzumab era: a systematic review by subtype. Ann Surg Oncol 2017;24:3124-32.
9. Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad, Boon WL, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008;26:2373-8.
10. Parker CC, Ampil F, Burton G, Li BD, Chu QD. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer? Surgery 2010;148:386-91.
11. Solin LJ, Hwang WT, Vapiwala N. Outcome after breast conservation treatment with radiation for women with triple-negative early-stage invasive breast carcinoma. Clin Breast Cancer 2009;9:96-100.
13. Hwang ES, Lichtensztajn DY, Gomez SL, Fowble B, Clarke CA. Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. Cancer 2013;119:1402-11.
15. Vila J, Gandini S, Gentilini O. Overall survival according to type of surgery in young (≤40 years) early breast cancer patients: a systematic meta-analysis comparing breast-conserving surgery versus mastectomy. Breast 2015;24:175-81.
16. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
18. Chen QX, Wang XX, Lin PY, Zhang J, Li JJ, Song CG, et al. The different outcomes between breast-conserving surgery and mastectomy in triple-negative breast cancer: a population-based study from the SEER 18 database. Oncotarget 2017;8:4773-80.
19. Wang J, Xie X, Wang X, Tang J, Pan Q, Zhang Y, et al. Locoregional and distant recurrences after breast conserving therapy in patients with triple-negative breast cancer: a meta-analysis. Surg Oncol 2013;22:247-55.
20. Lee SK, Kim SW, Yu JH, Lee JE, Kim JY, Woo J, et al. Is the high proportion of young age at breast cancer onset a unique feature of Asian breast cancer? Breast Cancer Res Treat 2019;173:189-99.
22. O’Rorke MA, Murray LJ, Brand JS, Bhoo-Pathy N. The value of adjuvant radiotherapy on survival and recurrence in triple-negative breast cancer: a systematic review and meta-analysis of 5507 patients. Cancer Treat Rev 2016;47:12-21.
24. Baeg S, Park I, Kim J, Park C, Cho H, Yang K, et al. Comparative study for clinical outcomes of triple-positive and triple-negative breast cancer: long-term results in 161 patients followed in a single center. J Breast Dis 2020;8:78-84.